drugset / Trial / NCT00130338

Rivastigmine Capsules in Patients With Probable Vascular Dementia

NCT00130338

Phase 3 Completed 521 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Timeline

Start
2002-02
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivastigmine Small molecule

Indications